Literature DB >> 16034131

The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production.

Azzeddine Dakhama1, Jung-Won Park, Christian Taube, Anthony Joetham, Annette Balhorn, Nobuaki Miyahara, Katsuyuki Takeda, Erwin W Gelfand.   

Abstract

Respiratory syncytial virus (RSV) infection in early life is suspected to play a role in the development of post-bronchiolitis wheezing and asthma. Reinfection is common at all ages, but factors that determine the development of altered airway function after reinfection are not well understood. This study was conducted in a mouse model to define the role of age in determining the consequences on airway function after reinfection. Mice were infected shortly after birth or at weaning and were reinfected 5 wk later, followed by assessment of airway function, airway inflammation, and lung histopathology. Infection of mice at weaning elicited a protective airway response upon reinfection. In this age group, reinfection resulted in increased airway inflammation, but without development of airway hyperresponsiveness (AHR) or eosinophilia and decreased IL-13 levels. By contrast, neonatal infection failed to protect the airways and resulted in enhanced AHR after reinfection. This secondary response was associated with the development of airway eosinophilia, increased IL-13 levels, and mucus hyperproduction. Both CD4- and CD8-positive T cells were a source of IL-13 in the lung, and inhibition of IL-13 abolished AHR and mucus production in these mice. Inoculation of UV-inactivated virus failed to elicit these divergent responses to reinfection, emphasizing the requirement for active lung infection during initial exposure. Thus, neonatal RSV infection predisposes to the development of airway eosinophilia and enhanced AHR via an IL-13-dependent mechanism during reinfection, whereas infection at a later age protects against the development of these altered airway responses after reinfection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16034131     DOI: 10.4049/jimmunol.175.3.1876

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  74 in total

Review 1.  Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.

Authors:  Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

2.  Immunomodulation with IL-4R alpha antisense oligonucleotide prevents respiratory syncytial virus-mediated pulmonary disease.

Authors:  Michael J Ripple; Dahui You; Srinivasa Honnegowda; Joseph D Giaimo; Andrew B Sewell; David M Becnel; Stephania A Cormier
Journal:  J Immunol       Date:  2010-09-22       Impact factor: 5.422

3.  Susceptibility to vaccinia virus infection and spread in mice is determined by age at infection, allergen sensitization and mast cell status.

Authors:  Joanne Domenico; Joseph J Lucas; Mayumi Fujita; Erwin W Gelfand
Journal:  Int Arch Allergy Immunol       Date:  2012-01-26       Impact factor: 2.749

4.  Thomas L. Petty Aspen Lung Conference: Asthma: Insights and Expectations. Conference summary.

Authors:  Homer A Boushey
Journal:  Proc Am Thorac Soc       Date:  2009-05-01

Review 5.  Neonatal immunology: responses to pathogenic microorganisms and epigenetics reveal an "immunodiverse" developmental state.

Authors:  Becky Adkins
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

6.  Responsiveness to respiratory syncytial virus in neonates is mediated through thymic stromal lymphopoietin and OX40 ligand.

Authors:  Junyan Han; Azzeddine Dakhama; Yi Jia; Meiqin Wang; Wanjiang Zeng; Katsuyuki Takeda; Yoshiki Shiraishi; Masakazu Okamoto; Steven F Ziegler; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

7.  Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Authors:  Junyan Han; Katsuyuki Takeda; Meiqin Wang; Wanjiang Zeng; Yi Jia; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

8.  Pulmonary surfactant phosphatidylglycerol inhibits respiratory syncytial virus-induced inflammation and infection.

Authors:  Mari Numata; Hong Wei Chu; Azzeddine Dakhama; Dennis R Voelker
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

9.  New mouse model of pulmonary hypertension induced by respiratory syncytial virus bronchiolitis.

Authors:  Dai Kimura; Jordy Saravia; Sridhar Jaligama; Isabella McNamara; Luan D Vu; Ryan D Sullivan; Salvatore Mancarella; Dahui You; Stephania A Cormier
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-06-15       Impact factor: 4.733

Review 10.  Respiratory viruses and eosinophils: exploring the connections.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Joseph B Domachowske
Journal:  Antiviral Res       Date:  2009-04-16       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.